Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.030 +0.220 (+12.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9
Via Investor Brand Network
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
From Cellares
Via Business Wire
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/24
Via Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/23
Via Investor Brand Network
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 9/12
Via Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 8/23
Via Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 8/18
Via Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 7/18
Via Investor Brand Network
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 7/12
Via Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 5/18
Via Investor Brand Network
Cabaletta Bio to Present at the Jefferies Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 5/2
Via Investor Brand Network
Cabaletta Bio Announces Proposed Public Offering of Common Stock
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.